Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Date of authorisation: 09/12/2009, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Date of authorisation: 30/09/2008, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Date of authorisation: 18/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Zokovea, ensitrelvir, Date of authorisation: 18/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Tacquell, Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded, Date of refusal: 14/09/2026, Status: Refused

CHMP opinions on consultation procedures on ancillary substances incorporated in a medical device